The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.
Alebund Pharmaceuticals Raises $54 5 Million in Series B+ Financing Round to Fuel Development of Renal Disease Treatment apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases
News provided by
Share this article
Share this article
SHANGHAI, May 9, 2021 /PRNewswire/ Alebund Pharmaceuticals ( Alebund or the Company ), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised $60 million in its Series B financing round which was led by Quan Capital, and followed by a prominent sovereign wealth fund, 3E Bioventures Capital, and Sherpa Healthcare Partners. Existing Shareholders, Lilly Asia Ventures and Med-Fine Capital, also took part in this financing round. Proceeds raised from this round will be invested in the research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion of Company s talent po
Alebund Pharmaceuticals, a Shangai, China-based biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, raised $60m in Series B financing.
The round was led by Quan Capital, with participation from 3E Bioventures Capital, and Sherpa Healthcare Partners and existing shareholders Lilly Asia Ventures and Med-Fine Capital.
The company intends to use the funds for research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion its talent pool.
Founded in Shanghai in early 2018 as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures, Alebund is a clinical stage biopharmaceutical company dedicated to the discovery and development of novel therapies and providing clinical solutions to patients with kidney diseases and related chronic conditions.